The basic treatment of prostate cancer programs

At present, according to the stages of prostate cancer, treatment options used are as follows:

Period of rule A1 prostatic hyperplasia discovered by chance when the cancer, limited disease, the majority of well-differentiated, the majority of patients in stable condition, the slow development, only about 1% may die of cancer. As the prognosis is good, generally not in favor of immediate radical prostatectomy surgery or radiotherapy, endocrine therapy. Regular follow-up, the digital rectal examination and B-ultrasonography, serum acid phosphatase. Can be treated with traditional Chinese medicine to control its development.

A1 period may not be used for treatment of patients with 35% of tumor progress, it should consider radical prostatectomy surgery or radiation therapy.

B1 the majority of tumor differentiation period is better, but surgery found that 5% -20% of patients have lymph node metastasis, it should be held in radical surgery for prostate cancer, after radical mastectomy 15 years cancer-free survival rate was 50% -70% .

B2 phase, about 50% of patients with seminal vesicle tumor has been violated, while 25% -35% of cases with lymph node metastasis and should be pre-cancer radical surgery and pelvic lymph node dissection, testicular surgery, endocrine therapy, radiotherapy and radiotherapy and other organizations. B2 phase after radical operation for 15 years cancer-free survival rate was 25%.

C period of treatment there is no consensus, so when treatment is more difficult to have the majority of pelvic lymph node metastasis. General treatment of the following methods: ① frail elderly, in patients with poor general condition, suitable for the expansion of the scope of radiation therapy in vitro. ② endocrine therapy (including two-testicular surgery), after treatment by the demotion, the scope for expansion in vitro, as well as prostate cancer radiotherapy combined with radical surgery. ③ organization and in vitro radiotherapy radiotherapy for non-lymph node metastasis and distant metastasis, and better from the body.

D phase to endocrine, chemotherapy and immune therapy based on the D0, D1 may be for the purposes of pelvic lymph node dissection, early use of hormonal therapy may extend survival time of tumor, 5-year survival rate of 30%.